PATIENT I
Anne L., a 48-year-old woman (5 ft 4 in, 125 lb), reported to her gynecologist
that she had been extremely tired, physically weak, and did not have the
energy to do her job. Upon questioning, she noted having very heavy
menstrual periods lasting for 1 1/2 to 2 weeks. Her hemoglobin was 6.1 g/dL;
hematocrit, 19%; MCV (mean corpuscular volume), 70 fL; MCHC (mean
corpuscular hemoglobin concentration), 27 g/dL.
4. If Anne is transfused, what would be the recommended component
and how many?
5. a. If she is transfused with 3 U of packed cells, what would
you estimate her hemoglobin and hematocrit to be following
transfusion?
b. Would you expect the elevation to be slightly higher or
lower than normal based on her size?
PATIENT 2
Carl M., a 50-year-old man, was scheduled for a colon resection. The preop
orders included a CBC and crossmatch for 2 U. The CBC report was white
blood cells (WBCs), 14.5 x 109/L; hemoglobin, 14.0 g/dL; hematocrit, 43%;
platelet count, 19,000/uL. The blood bank technologist typed him as 0 positive
and cross-matched 2 U of 0-positive packed cells.
6. Is additional component therapy other than the 2-U crossmatch
indicated? Why?
7. How many units of the second component should be ordered?
8. Calculate the approximate platelet count following transfusion,
assuming a 70-kg man.
9. a. If Carl’s 1-hour post-transfusion platelet count is
40,000/uL, what is his corrected count increment (CCI)?
(Assume a body surface area of 1.5 m2.)
b. Is it normal, higher, or lower than expected?
c. What does this indicate?
10. What are the storage temperature and shelf-life of platelets?
PATIENT 3
Melissa G., a 20-year-old woman who had been diagnosed with von Willebrand’s disease, was
scheduled for elective surgery. Her physician wanted to stabilize her von Willebrand’s factor (vWF)
before surgery and ordered a therapeutic trial of l-deamino-8-D-arginine vasopressin (DDAVP)
(Stimate [desmopressin]), a non-blood treatment that increases the release of vWF from storage
sites (endothelial lining of blood vessels). She was a weak responder, and her vWF levels did not
increase adequately; therefore, the next option was to use blood component therapy. Melissa had
approximately 20% of the normal concentration of vWF.
11. What would you expect Melissa’s results to be on the following coagulation
tests (increased, normal, or decreased)?
a. Prothrombin time (PT)
b. Activated partial thromboplastin time (APTT)
c. Platelet count
d. Bleeding time
e. VIII:C
f. Ristocetin-induced platelet aggregation (RIPA)
12. Why did the physician try nonblood treatment before ordering blood component
replacement therapy?
13. What is/are the component(s) of choice for stabilizing the concentration of vWF?
We are a professional custom writing website. If you have searched a question and bumped into our website just know you are in the right place to get help in your coursework.
Yes. We have posted over our previous orders to display our experience. Since we have done this question before, we can also do it for you. To make sure we do it perfectly, please fill our Order Form. Filling the order form correctly will assist our team in referencing, specifications and future communication.
1. Click on the “Place order tab at the top menu or “Order Now” icon at the bottom and a new page will appear with an order form to be filled.
2. Fill in your paper’s requirements in the "PAPER INFORMATION" section and click “PRICE CALCULATION” at the bottom to calculate your order price.
3. Fill in your paper’s academic level, deadline and the required number of pages from the drop-down menus.
4. Click “FINAL STEP” to enter your registration details and get an account with us for record keeping and then, click on “PROCEED TO CHECKOUT” at the bottom of the page.
5. From there, the payment sections will show, follow the guided payment process and your order will be available for our writing team to work on it.
Need this assignment or any other paper?
Click here and claim 25% off
Discount code SAVE25